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Abstract  
Small heat-shock proteins (sHsps) are a diverse family of intracellular molecular chaperone proteins that play a 
critical role in mitigating and preventing protein aggregation under stress conditions such as elevated temperature, 
oxidation and infection. In doing so, they assist in the maintenance of protein homeostasis (proteostasis) thereby 
avoiding the deleterious effects that result from loss of protein function and/or protein aggregation. The chaperone 
properties of sHsps are therefore employed extensively in many tissues to prevent the development of diseases 
associated with protein aggregation. Significant progress has been made of late in understanding the structure and 
chaperone mechanism of sHsps. In this review, we discuss some of these advances, with a focus on mammalian 
sHsp hetero-oligomerisation, the mechanism by which sHsps act as molecular chaperones to prevent both 
amorphous and fibrillar protein aggregation, and the role of post-translational modifications in sHsps chaperone 
function, particularly in the context of disease. 
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Introduction 
The proteome is inherently meta-stable [1,2]. Arguably, the most important means nature uses to maintain the 
integrity of the proteome (termed proteostasis) is the network of molecular chaperone proteins, which are present 
both intra- and extracellularly. The abundant and ubiquitous small heat-shock proteins (sHsps) are a family of 
intracellular molecular chaperones that interact with partially folded target proteins to stabilise and prevent their 
aggregation and precipitation. They do so under constitutive conditions but many sHsps are particularly prevalent 
under stress conditions when their expression is significantly up-regulated. The sHsps have a wide tissue 
distribution and, as a result, are associated with a plethora of disease states, particularly those related to 
compromised proteostasis (e.g. involving defective protein folding).  In the eye lens, for example, the high 
concentration of the two major sHsps, A- and B-crystallin, prevents protein aggregation, in addition to ensuring 
proper lens transparency. Recently, excellent reviews on the structure and functions of various sHsps have been 
published, all aimed at contributing to and better describing their as yet ill-defined mode of chaperone action and 
their roles in physiological and pathological processes [3-7]. As stated by Mymrikov et al.[5], ‘the amount of 
information in this field is accumulating very rapidly’ as we draw incrementally closer to the practical application 
of this knowledge in the prevention and treatment of disease. In this review, we summarise recent research into 
sHsp structure, function and interactions. Following a brief introduction to the structure and chaperone action of 
sHsps, we focus on the importance of hetero-oligomerisation and post-translational modification (primarily 
phosphorylation) to sHsp chaperone action and the ability of members of this protein family to successfully 
stabilise target proteins undergoing either amorphous or fibrillar aggregation. In the context of their impacts on 
normal chaperone function, we also examine the effects of naturally-occurring sHsp mutations that result in human 
diseases such as cataract, peripheral myopathies and neurodegenerative diseases.  
Since sHsps are intracellular molecular chaperones, this review focusses on the ability of sHsps to mitigate and 
prevent protein aggregation inside the cell. However, protein aggregation also occurs in the extracellular 
environment where there is a set of molecular chaperones that function to minimise the deleterious effects of 
protein aggregation (recently reviewed in [8]). The best characterised extracellular molecular chaperone is 
clusterin, which was also the first to be described [9]. Clusterin, like the other extracellular chaperones, is unrelated 
to the sHsps, yet it functions in a very similar chaperone manner to the sHsps to prevent protein aggregation [10].  
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SECTION I: The structure and function of sHsps 
Each sHsp is comprised of three regions: N- and C-terminal regions which are separated by a highly conserved 
-crystallin domain (ACD) of approximately 80 amino acids in length that is a defining characteristic of all sHsps 
(Figure 1A).  By contrast, the N- and C-terminal flanking regions are variable in length between the sHsps and 
lack significant sequence similarity. The structures of mammalian sHsps have proved difficult to decipher. Of 
late, a battery of powerful and complementary techniques, i.e. X-ray crystallography, solid-state and solution 
NMR spectroscopy, small-angle X-ray scattering (SAXS), small-angle neutron scattering (SANS), mass 
spectrometry and cryo- and transmission electron microscopy (cryo-EM and TEM, respectively) have been 
utilised to gain unprecedented insight into the structure of sHsps. We shall only discuss the salient structural 
features that have become apparent from these studies as more in-depth discussion has been presented in recent 
reviews of sHsp structure [3,7,11,12].  
 
The subunit monomeric mass of sHsps ranges from 15 to 40 kDa, however their classification (and nomenclature) 
as sHsps is somewhat of a misnomer as they typically exist as large, spherical, oligomeric species in solution. In 
the case of Bc, these oligomers are highly heterogeneous with a mass range under physiological conditions, as 
determined by light scattering, of 420 – 980 kDa [13] and an average mass of approximately 650 kDa [14]. 
Moreover, sHsps are highly dynamic species as there is extensive subunit exchange between oligomers which 
may be important in their chaperone function [15].  In addition, the dynamic nature of sHsps is also due to large 
portions, particularly within the N- and C-terminal regions, having little well-defined secondary structure and 
exhibiting flexibility. The extreme C-terminus, within the C-terminal region, is very much so with solution-phase 
NMR spectroscopy revealing that the last 10 and 12 amino acids in Ac and Bc respectively are unstructured 
C-terminal extensions that have mobility comparable to isolated peptides of the same length [16-19]. Similarly, 
other mammalian sHsps have highly flexible C-terminal extensions [17,18]. The heterogeneity, dynamism and 
flexibility of mammalian sHsps have inhibited crystallisation attempts of the full-length proteins, however X-ray 
crystal structures are available for some non-mammalian sHsps which lack the flexible C-terminal extensions and 
form well-ordered oligomers, e.g. of Hsp16.5, a 24-mer from a hyperthermophilic archeon Methanococcus 
jannaschii  [20] (Fig. 1B) and Hsp16.9, a 12-mer from wheat [21].  
 
There is much evidence, e.g. from X-ray crystallography and mass spectrometry [22], that the building block of 
the sHsp oligomer is a dimer. The crystal structures of the isolated ACD from Bc [23], Hsp27 [24] and Hsp20 
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[23] have confirmed this dimer arrangement and the predicted features of this domain, i.e. that it is highly -sheet 
in character and arranged in an immunoglobulin-like fold. Structures of the ACD of Ac and Bc that also 
contained the majority of the C-terminal region, but not the C-terminal extension, were recently solved [25]. These 
structures demonstrated that a -strand (numbered 6 and 7) from each monomer, via an anti-parallel arrangement, 
provides the inter-subunit (i.e. intra-dimer) interface [25] (Fig. 1C). Furthermore, the conserved I-X-I motif (I159-
P160-I161 in Bc) in the C-terminal region of one subunit can bind in a groove formed between the 4 and 8 
strands on a subunit of an adjacent dimer, forming the inter-dimer interface [26] (Fig. 1C). The I-X-I motif is the 
central part of a nine amino acid palindromic sequence that enables equivalent interactions in both directions of 
the polypeptide chain with other subunits. As a result, this region facilitates polydisperse oligomerisation. Crystal 
formation is deleterious to lens transparency and this palindromic sequence may be the crucial factor in inhibiting 
Bc crystallisation and in enabling dynamic interactions both with itself (via subunit exchange) and its target 
protein during chaperone action. 
 
In agreement with the X-ray crystallographic studies, a solution and solid-state NMR and SAXS investigation of 
full-length Bc concluded that the ACD adopts an immunoglobulin-like -sheet structure [27]. Subsequent solid-
state NMR studies concluded that the N-terminal flanking region has two short helices and a small stretch of anti-
parallel -sheet near the boundary with the ACD [28]. The heterogeneity of NMR resonances, however, implied 
that significant conformational mobility exists in the N-terminal region. From these data, in combination with 
TEM and SAXS measurements, a model for the quaternary arrangement of Bc was constructed based around a 
core 24-mer to which dimers can be added [28]. 
 
On this latter point, the quaternary structure of Bc has been studied for many years, yet there is no agreement as 
to the precise quaternary arrangement of mammalian sHsp oligomers with various models proposed (summarised 
in [29]). Cryo-EM studies show that under physiological conditions, the human Bc oligomer forms large roughly 
spherical assemblies of 8-18 nm in diameter [14,30]. Under partially denaturing conditions and elevated 
temperature, Bc also assembles into amyloid fibrils as revealed by TEM and atomic force microscopy [31,32]. 
Cryo-EM reconstructions applied to native Bc oligomers  suggest a dynamic and variable asymmetric quaternary 
structure, with a roughly spherical protein shell of average diameter ~15 nm which surrounds a large central cavity 
of ~8 nm in diameter [14,30,33]. The oligomer is characterised by having large openings in the shell leading to 
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the interior  [34]. A large central cavity is characteristic of sHsp oligomers (Fig. 1B), as was predicted from simple 
consideration of polypeptide occupancy within such oligomers [35]. 

-Crystallin in the lens 
In humans, there are ten sHsps (HSPB1-10), the predominant being A-crystallin (Ac, HSPB4), B-crystallin 
(Bc, HSPB5), Hsp27 (HSPB1) and Hsp20 (HSPB6). -Crystallin (c), the complex between Ac and Bc 
subunits (at a 3:1 molar ratio of Ac to Bc in humans [36]) that is present in the eye lens, along with the other 
crystallins ( and ), form a concentrated, closely associated and ordered array that enables proper refraction of 
light through the lens and its focusing onto the retina. Cis the principal lens protein and, like its individual 
subunits, c forms large, heterogeneous, oligomeric and dynamic complexes, in this case of ~160 to 1,000 kDa 
in mass [22,30,37]. X-ray and neutron solution scattering experiments have shown that c increases in size 
significantly at higher temperature [38-42] such that the radius of gyration changes from 69 ± 3 Å to 81 ± 5 Å 
following incubation at 65oC [40]. This change is not reversed by cooling, in contrast to the behaviour of c at 
high pressure where reversibility is observed [42]. Neutron scattering experiments of complexes formed between 
c and E-crystallin at high temperature (65oC) demonstrated that the latter binds inside the central cavity of c 
[40] most likely becoming more surface-exposed at higher temperature due to major structural rearrangements 
(including partial unfolding) that occur to c at these temperatures leading to exposure of the core of the oligomer. 
Access to the core would be facilitated by the porous nature of the c oligomer [34], i.e. the presence on its surface 
of openings or ‘fenestrations’ [39].  Interestingly, under milder stress conditions, target proteins are probably 
located in the ‘fenestrations’ rather than inside the oligomer cavity [39,43] implying that c has a variety of modes 
of interaction with target proteins, depending on the stress conditions.  
 
For many years, c was regarded as simply a ‘filler’ protein that was only found in the lens in high concentrations 
to ensure proper lens transparency. This situation is certainly not true nowadays. Major research interest in c 
(and sHsps in general) was sparked by two seminal observations: (1) Bhat and Nagineni’s finding [44] that c 
is present in many non-lens tissues and (2) Horwitz’s identification of the molecular chaperone activity of c 
whereby it prevents the aggregation and precipitation of a diversity of proteins under stress conditions, e.g. 
elevated temperature [45]. Horwitz’s observation was an experimental verification of Ingolia and Craig’s earlier 
classification of c as a member of the sHsp molecular chaperone family [46]. In the lens, the chaperone ability 
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of c is of paramount importance in that it prevents the aggregation and precipitation of the crystallin proteins 
and hence delays the onset of age-related cataract. In this section we will discuss the role of c in the lens. 
C possesses two interlinking characteristics within the eye lens that are crucial to maintaining lens transparency 
and hence visual acuity, namely its structural organisation and its chaperone activity. Firstly, however, it is helpful 
to describe the unusual environment of the lens to gain a further appreciation of the importance of c’s biological 
role in this tissue. The avascular eye lens, surrounded by a collagen rich capsule, is composed of fibre cells, which 
develop from the single layer of epithelial cells on the anterior surface of the lens [47]. The lens fibre cells undergo 
a differentiation process involving cell elongation, expression of the predominant lens proteins, the crystallins  
[48], and degradation of cellular organelles, including the removal of nuclei [47,49-51]. This loss of cellular 
organelles is thought to aid lens transparency, by removing potentially light scattering structures from the light 
path [50].  Lens transparency is limited by absorption and scattering of visible light. Visible light absorption is 
usually negligible for eye lenses since the electronic energy level separations of proteins in general, and thus 
including the crystallins, are too great to enable molecules to be promoted to the excited state upon irradiation by 
visible light. Lens transparency is thus determined by scattering of light by the lens cytoplasm protein solution 
[52].   
 
Crystallin protein concentration has been estimated at approximately 200 mg/mL in the outer lens cortex, and up 
to 460 mg/mL in the central lens nucleus [53,54]. Despite this extremely high protein concentration and high 
degree of organisation in the lens, the crystallin proteins do not crystallise, and are free to move  [52]. The 
crystallins are organised in a highly stable supramolecular -sheet structure within the lens [55-57]. Lens 
transparency is proposed to be maintained by a liquid-like, short-range order in the highly concentrated crystallin 
solutions, as found in dense liquids or glasses [58]. C comprises 30-40% w:w of the lens soluble protein [33,59], 
and is thus a key player in this highly organised structural array.  
 
The loss of cellular organelles in the lens renders the lens fibre cells incapable of protein synthesis, hence there is 
almost no protein turnover in the lens. Consequently, the crystallin proteins must be maintained in a stable state 
throughout the lifespan of the organism. The chaperone action of c in preventing the aggregation of itself and - 
and -crystallins [45,60-62] is therefore especially important in the lens given the absence of cellular organelles 
and lack of new protein production. Indeed, it has been proposed that the reason for the predominance of Ac 
over Bc in the lens is that Ac acts as a chaperone for Bc, which is intrinsically less stable than Ac [60,63]. 
8 
 
 
Expression and function of sHsps extra-lenticularly 
Bhat and Nagineni’s [44] and Horwitz’s [45] discoveries are highly interconnected: the extensive extra-lenticular 
expression of c and other sHsps unquestionably arises from their fundamental chaperone activity, i.e. nature 
has utilised their activity in many and varied roles in cells in order to maintain proteostasis. In addition to the lens, 
Bc is also located in many parts of the body and is found at high levels in the retina, heart, skeletal muscle, skin, 
brain, spinal cord, kidneys, lungs [44,64,65], the cochleae of the mammalian ear [66], and the lacrimal gland duct 
and tears [67]. Ac is present, albeit to a much lesser extent, for example in the spleen and thymus [68]. Outside 
of the lens, Bc has a wide variety of metabolic and regulatory functions [69,70]; expression is induced by stress, 
for example by pH extremes, elevated temperature, chemical or heavy metal exposure, or hypertonic stress [71-
73] and this confers both thermotolerance [74] and protection against oxidative stress to cells [75,76]. 
 
Many of the other members of the sHsp family exhibit wide extra-lenticular tissue distribution with Hsp20, for 
example, being constitutively and highly expressed in all types of muscle [6]. Hsp22 (HSPB8), Hsp27 and Bc 
are also present in muscle cells, along with being expressed in many other cell types including neurons [6]. The 
extra-lenticular expression of the major sHsps is summarized in Table 1. 
 
Outside the lens, the sHsps play a vital role in maintaining cell viability under stress conditions: .they can reach 
levels of up to 1% of the total cellular protein pool following stress and they are the most acutely induced of the 
heat-shock proteins (Hsps). Moreover, the sHsps are an integral component of the proteostasis network in cells 
and their chaperone (mal)function and/or over-expression is associated with many diseases, e.g. 
neurodegenerative diseases, various cancers, cataract, cardiomyopathies and multiple sclerosis [77,78] (see 
Section III). The significance of sHsp malfunction in the context of disease is exemplified by the development of 
therapeutics that target expression of one sHsp, Hsp27, for the treatment of bladder, prostate and pancreatic 
cancers [79]. The common theme from this work is that failure of sHsps to act, through their chaperone activity, 
to stabilise target proteins and prevent their improper interactions in cells can cause disease.  
Hetero-oligomerisation of sHsps 
Whilst much work has focussed on the structure and function of homo-oligomeric forms of sHsps (see discussion 
above), in vivo sHsps most likely exist predominately as hetero-oligomers. For example, both Hsp27 and αBc are 
expressed in the kidneys, bladder, lungs, stomach, cardiac and skeletal muscle [73,80-82] and co-localise in both 
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normal and pathological tissues of neurodegenerative patients [80,83,84]. Moreover, they associate, to a partial 
degree, with each other in these tissues [85] and in stably transfected HeLa cells expressing wild type or the 
disease-causing mutant R120G Bc [86]. Mixing of subunits is facilitated by the dynamic subunit exchange of 
mammalian sHsps [15,87,88] and is proposed to play a functional role in chaperone action (see next section). We 
have recently used mass spectrometry to quantify the rate of subunit exchange from Hsp27 and αBc homo-
oligomers to form hetero-oligomers, and characterise the end products [89]. The rate of subunit exchange between 
Hsp27 and Bc was more rapid than that reported for Hsp27 and Ac, and Ac and Bc [87,89]. The hetero-
oligomers had masses and thermo-stabilities intermediate to those of the homo-oligomers and their chaperone 
ability was equivalent to that of αBc (and better than Hsp27).  
 
To-date, there is also evidence for the formation of hetero-oligomeric complexes between αA- and αBc, as occurs 
in the lens [44,61], αAc and Hsp27 [87], HspB2 and HspB3 [90,91], αBc and Hsp20 [92] and Hsp27 and Hsp20 
[88]. However, caution is required in interpreting work that has involved adding a bulky tag directly to the sHsps  
to measure sub-unit exchange (for example, adding green fluorescent protein or one of its derivatives for 
fluorescence energy transfer studies) as these can directly interfere with the dynamism of the sHsps, their ability 
to form oligomers and thus their chaperone function [93,94]. The formation of hetero-oligomers between sHsps 
is temperature dependent [15,87,88,95] and, upon heat shock, the hetero-oligomeric assemblies of Hsp27 and αBc 
in cells dissociate and reform once the cell has recovered [85]. This raises questions as to whether homo- and 
hetero-oligomeric forms of sHsps play different functional roles in the cells. For example, variation in the subunit 
composition of hetero-oligomers (as opposed to homo-oligomers) may influence the interaction with and binding 
of target proteins and therefore facilitate interactions with some cellular components in preference to others.  
 
The chaperone mechanism of sHsps 
The sHsps are typically classified as ‘holdase’ chaperones, however, this description does not fully describe the 
multi-faceted nature by which they can interact with target proteins to prevent their aggregation. Whilst the sHsps 
can bind tightly to, and form high-molecular-mass complexes with, destabilised protein intermediates to maintain 
them in a refolding competent state (for example, so that they are amenable to refolding by ATP-dependent 
chaperones such as Hsp 70, when cellular conditions permit [96]), they can also interact with target proteins in a 
weak and transient manner, briefly stabilising them in order to facilitate their intrinsic ability to refold back to 
their native (functional) state. For example, αBc forms stable high-molecular-mass complexes with disordered, 
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precipitation-bound intermediates of the target protein -lactalbumin that expose significant amounts of 
hydrophobicity to solution but also interacts through weak, transient interactions to suppress the aggregation of 
relatively stable -lactalbumin intermediates that expose less hydrophobicity to solution [43,97-100]. The weak 
transient interactions with target proteins is the mechanism that most likely predominates in cells that are not 
subjected to stress since these conditions are not conducive to large-scale protein destabilisation. Thus, it is 
envisaged that sHsps only mediate stable high-molecular-mass complex formation with protein intermediates (i.e. 
act as ‘holdases’) when binding is more energetically favourable than refolding. As such, their broad mechanism 
of action indicates that a more apt description of sHsp chaperones is as ‘stabilisers’ rather than ‘holdases’. 
 
Currently, no well-defined target protein binding site(s) has been identified for mammalian sHsps. Various studies 
have suggested that target protein binding is mediated by the N-terminal domain [101-104] or the ACD [105-
107]. Indeed, with regards to the latter, we [26] and others [25,27,108] have shown that isolated ACDs exhibit 
chaperone function. Sharma and colleagues have shown that ‘mini’ chaperones comprised of only residues 70-88 
of Ac within its ACD and the corresponding residues (73 – 92) of Bc act as efficient chaperones in their own 
right [105,109]. Moreover, target protein binding may also be regulated by multiple regions of the sHsp. For 
example, it has been recently suggested that target protein access to a binding site formed between -sheets 4 and 
8 in Bc’s ACD is regulated by auto-inhibitory docking of the C-terminal I-X-I hinge region into this groove, i.e. 
at the inter-dimer interface (Fig. 1C) [29,107]. In this case, hydrophobic target proteins compete with this C-
terminal region for binding at this site on Bc. The overall emerging picture is that there is no single target protein 
binding site on sHsps, rather binding is mediated by hydrophobic sites on the surface of the sHsp and these sites 
of interaction vary depending on the sHsp and target protein in question. Intriguingly, as discussed above, the 
central cavity of sHsps also appears to play a role in sHsp chaperone action, for example under conditions of 
severe stress [40,43,110]. 
 
The remarkable ability of sHsps to distinguish disordered protein intermediates from stable (native-like) 
intermediates is proposed to be based upon the intermediate’s free energy of unfolding [111], the lifetime of the 
intermediate and its relative degree of exposed hydrophobicity [97]. To-date, the most widely accepted model of 
sHsp chaperone action is that dissociated species (normally depicted as dimers) are the more chaperone-active 
species and large oligomers are ‘reservoirs’ of these species; the dissociated species associate with target proteins 
and then can re-associate with the large oligomers to form high-molecular-mass sHsp-target protein complexes. 
11 
 
This model is favoured because it is thought that (i) the dissociated species would expose more surface 
hydrophobicity to solution and therefore be more capable of binding to destabilised target proteins and, (ii) the 
chaperone activity of sHsps is dependent on subunit exchange. Recent work, including our own, has shed further  
light on the multi-faceted manner by which sHsps interact with aggregation-prone proteins, particularly those 
aggregating to form amyloid fibrils (reviewed in [37]). In summary, this work has demonstrated that sHsps can 
interact with monomeric, oligomeric, prefibrillar and fibrillar forms of target protein in order to prevent their 
aggregation, i.e. at each stage of the amyloid fibril-forming pathway. Based on this work we propose an expanded 
model of the chaperone action of sHsps (Fig. 2). 
 
Most studies that have tested the in vitro chaperone action of sHsps have involved addition of the chaperone prior 
to aggregation commencing. Thus, the design of such studies does not address the effect(s) sHsps have on the 
latter stages of aggregation, which is as important to consider since, in vivo, levels of sHsps in the cell increase 
after aggregation has commenced as a result of the activation of the stress response [112,113]. Apart from 
interacting with monomeric species, sHsps also bind to species formed further along the aggregation pathway, 
including mature amyloid fibrils [114-117]. For example, when introduced during the elongation phase of -
synuclein (-syn) or amyloid- peptide (A aggregation, Bc prevents further fibril growth by binding along the 
length of mature fibrils, preventing secondary nucleation events that facilitate further fibril growth [114-116]. Our 
recent work, using apolipoprotein C-II (apoC-II) as a model fibril-forming protein, has shown that, by binding to 
fibrils, Bc stabilises them, preventing their (dilution-induced) fragmentation, and causes them to associate 
(tangle) into larger species reminiscent of protein inclusions [117]. Both fibril fragmentation and secondary 
nucleation can be the main sources of small oligomers thought to be responsible for the toxicity associated with 
the aggregation process [118]. Thus, the fibril-binding activity of sHsps helps to rationalise why sHsps (and indeed 
other Hsps) are found in protein deposits associated with disease, i.e. by binding to fibrils they facilitate their 
packing into inclusions, thereby limiting fibril fragmentation and secondary nucleation and providing an 
alternative protective mechanism to the cell. Recently Bc has also been shown to promote the dissociation of 
potentially toxic β2-microglobulin oligomers into monomers, highlighting another role these chaperones may have 
in cells to protect them from the adverse effects of protein aggregation [119].  
 
Despite our growing appreciation of the mechanisms by which sHsps interact with aggregating proteins there are 
still critical aspects of the chaperone model of sHsps that require further clarification: (1) There is no definitive 
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evidence to-date that dissociated (dimeric) species are the sole chaperone active species (indeed for some sHsps 
such as Bc there is no direct evidence for the presence of dissociated species in solution) and some reports 
suggest that the large sHsp oligomers are also chaperone active [120,121]. For instance, some studies have 
indicated that there is no correlation between the concentration of sub-oligomeric species (or subunit exchange 
rate) and apparent chaperone activity [122]. Moreover, glutaraldehyde cross-linked c, which is incapable of 
subunit exchange, retains significant chaperone activity in vitro [121]. (2) Little is known about the stoichiometry 
of mammalian sHsp-target protein complexes. To-date, efforts to study, in precise detail, the manner by which 
sHsps bind to target proteins to form complexes have been hampered by the large, polydisperse and dynamic 
nature of sHsp oligomers and the low abundance of individual species in these heterogeneous samples. This 
problem is further confounded by the use of ‘bulk’ averaging techniques that can mask the presence of rare species 
formed in such dynamic systems. (3) The model is predominately based on in vitro studies of sHsp chaperone 
action; little is known about how this model relates to the chaperone activity of sHsps inside the crowded 
environment of the cell. For example, nothing is known about the precise concentrations of sHsps inside a cell 
(let alone cellular compartments such as the nucleus versus the cytoplasm) and since the oligomeric state of sHsps 
is concentration dependent (see discussion for Hsp27 below) it therefore remains to be elucidated which 
oligomeric forms are relevant in a cellular context.  
 
Defining the precise molecular mechanisms that underpin the chaperone activity of sHsps is essential for 
understanding their role in the suppression of aggregation in cells. Such knowledge will in turn inform efforts 
aimed at exploiting the biological activity of sHsps in the treatment of diseases.  
 
SECTION II: Role of post-translational modification in the structure/function of sHsps   
sHsps undergo a variety of post-translational modifications. For example in the lens, Acand Bc are subject to 
significant post-translational modification which includes phosphorylation, truncation (particularly within the 
unstructured C-terminal region), isomerisation, deamidation and glycation. In this section, we focus on 
phosphorylation as this post-translational modification occurs to sHsps in many tissues and, in the case of Acand 
Bc, occurs early on in life, including before birth [123-125]. Moreover, phosphorylation of some sHsps occurs 
under conditions of cellular stress (see below), and is reversible (through the action of phosphatases) and is 
therefore thought to have an important functional role in dynamically altering the oligomeric distribution and 
chaperone ability of sHsps in response to stress. 
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In contrast to phosphorylation, the other post-translational modifications are largely confined to the long-lived 
lens sHsps, Ac and Bc. Thus, they occur to a significant extent to these sHsps with age and are associated with 
aggregation of the crystallin proteins, and hence cataract formation. Within the lens, these modifications to the 
crystallins including Ac and Bc, have been well summarised in a recent review [126]. Some salient points from 
experimental studies of Ac and Bc modifications are described below. All of these modifications have the 
potential to destabilise the structure of the proteins leading to crystallin unfolding and aggregation that ultimately 
contributes to cataract formation.  
 
In vitro, it is well known that C-terminal truncation within the exposed C-terminal extension decreases the stability 
of both Ac and Bc, particularly when most of the extension is removed [15]. Even greater truncation, i.e. further 
in from the C-terminal extension and into the C-terminal region, leads to significant structural changes. For 
example, Q151X Bc, which contains the N-terminal region and the ACD but not the crucial I-X-I sequence, is a 
naturally occurring mutant that causes myopathy. Q151X Bc has little secondary structure and decreased 
oligomerisation and, in the presence of wild type Bc, both proteins co-aggregate [127]. Intriguingly, Q151X 
Bc still exhibits chaperone activity. Isomerisation of L-aspartic acid to its D-form is very prevalent in aged lens 
crystallins, including in Acand Bc [126]. Of course, the introduction of a D-amino acid into any protein affects 
the local structure in the vicinity of the modification which, in the case of lens Acand Bc, leads to the disruption 
of the supramolecular crystallin order within the lens. Deamidation occurs extensively to Ac and to Bc with 
age in the human lens [128] and also to the -crystallins (reviewed in [129]). Potentially, deamidation leads to 
destabilising structural changes due to the introduction of an additional negative charge from the resultant aspartic 
or glutamic acid sidechains [130]. Glycation is a common post-translational modification of lens Ac and Bc 
and is particularly associated with diabetes where increased levels of blood glucose are present [131,132]. 
Glycation leads to the formation of covalent cross-links, aggregation and compromised chaperone activity of c 
[8] with obvious implications for the development of diabetic cataract. 
 
Phosphorylation 
Both intra- and extra-lenticularly, the major post-translational sHsp modification is phosphorylation, the levels of 
which generally increase with age and under stress conditions [133-137]. For example, Bc is phosphorylated at 
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three serine residues, Ser19, Ser45 and Ser59 [136,138,139]; phosphorylation at Ser45 is mediated by p44/p42 
mitogen activated protein kinase (MAPK), at Ser59 by MAPK activated protein kinase 2 (MAPKAPK-2) 
[136,140], whilst the kinase responsible for phosphorylation at Ser19 remains to be identified. Similarly, Hsp27 
has three serine residues (Ser15, Ser78 and Ser82) that undergo phosphorylation [141,142]. MAPKAPK-2 is 
responsible for Hsp27 phosphorylation at all three sites [143,144]. In addition to Ac, Bc and Hsp27, 
phosphorylation is also common to other sHsps such as Hsp20 [145,146] and occurs readily in all tissues. 
Phosphorylation of Hsp20 occurs at Ser16 and is mediated by cyclic nucleotide-dependent protein kinases [147]. 
There have been other reports of sHsp serine phosphorylation (e.g. Hsp22 at Ser24 and Ser57 [148] and HSPB10 
at Ser193 [149]), however the kinases responsible for these phosphorylation events in vivo remain to be 
definitively established.  
 
The introduction of a strong negative charge via phosphorylation at serine residues in the N-terminal region of 
αBc and Hsp27 alters their oligomerisation state. Phosphorylation reduces the average oligomer size, and 
increases oligomeric polydispersity and rate of subunit exchange of αBc [104,150-152], whereas it leads to a 
dramatic decrease in the size of Hsp27 oligomers, such that the triply phosphorylated isoform is predominately 
dimeric in solution [153,154]. Thus, under stress conditions, Hsp27 is phosphorylated, triggering dissociation of 
the large Hsp27 oligomers [135,153,155,156] and an increase in the amount of exposed hydrophobicity on the 
newly formed Hsp27 dimers [157]. Phosphorylation also affects the cellular distribution of some sHsps. For 
example, following stress, phosphorylation of Bc and Hsp27 causes them to be translocated into the nucleus 
[158-162], presumably to protect nuclear proteins important to cell survival. Thus, phosphorylation of sHsps 
functions as a ‘molecular switch’ by regulating their structure and cellular localisation during periods of cellular 
stress. 
 
While purified αBc from bovine lens has been used to investigate of the effects of phosphorylation on αBc 
structure and function (as it is extensively phosphorylated with age [123,125,138,139,163]), such sources of sHsps 
do not afford homogeneous phosphorylated isoform. Instead these contain a mixture of non-phosphorylated, 
mono-, di- and/or tri-phosphorylated forms in the one oligomer. Denaturation and subsequent ion-exchange high 
performance liquid chromatography can be used to separate these phosphorylated forms [164,165], however 
denaturation modifies the oligomeric state and activity of αBc once it is refolded [166]. As an alternative, 
phosphomimics are useful tools to investigate the effects of phosphorylation upon sHsp structure and function. 
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Phosphomimics are created by replacing phosphorylatable serine residues with a negatively charged amino acid, 
such as aspartic acid or glutamic acid, to mimic the negative charge introduced by the addition of the phosphate 
group. The main advantage of phosphomimics is that they afford a single homogeneous isoform of the protein. 
Significantly, phosphomimics of Bc and Hsp27 have similar attributes to the phosphorylated forms of the protein 
with regards to their oligomeric distribution, chaperone activity, subcellular localisation and cellular trafficking 
[154,161,167,168].  For example, the translocation of αBc to the nucleus and its association with nuclear speckles 
during mitosis is phosphorylation-dependent and this is replicated by the S19D/S45D/S59D αBc phosphomimic 
[161] and both in vitro phosphorylated Hsp27 and the S15D/S78D/S82D Hsp27 phosphomimic have comparable 
abilities to prevent the aggregation of target proteins in vitro [154]. Both S59 phosphorylated and S59E 
phosphomimicking forms of Bc bind to the anti-apoptotic regulator Bcl-2, promoting apoptosis of breast cancer 
MCF7 cells and therefore making them more susceptible to chemotherapeutic agents [169].  
 
The precise effect that phosphorylation has on the chaperone function of sHsps remains controversial. For 
example, some studies have concluded that Hsp27 phosphorylation increases chaperone activity (for example, 
[154,156]), others have reported no difference  [170] whilst others have found that phosphorylation decreases 
activity  [153]. Similar discrepancies exist in the literature with regards to the effect of phosphorylation on Bc’s 
chaperone activity [151,152,165,167]. Various factors may account for these apparent differences including the 
target protein used to assess the chaperone activity, the final concentration of sHsp in the assays (wild-type Hsp27 
dissociates at low concentrations and therefore may be predominately dimeric, like the phosphorylated form, in 
some assays [154,156]), and buffer and temperature conditions of the assay, all of which influence sHsp chaperone 
activity [151]. Overall, the consensus emerging from work with Bc and Hsp27 concerning the impact of 
phosphorylation on sHsp chaperone function is that phosphorylation boosts chaperone activity and does so by (i) 
promoting dissociation of large oligomers into smaller species [104,150,151,153,154] and (ii) enhancing their 
affinity to bind destabilised target proteins [111,156]. Based on structural modelling of a full-length Bc into a 
24-mer oligomer [171], recent work has concluded that the negative charges introduced into the N-terminal 
domain of Bc by phosphorylation at S19, S45 and S59 result in oligomer destabilisation and dissociation due to 
the close proximity of adjacent N-terminal domains in the higher-order oligomeric structure [104]. Moreover, 
phosphorylation increases the rate of subunit exchange between oligomers and the flexibility of the N-terminal 
domain, leading to an increase in chaperone activity [104].  
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With regards to the overall impact of sHsp phosphorylation in a cellular context, it is envisaged that under normal 
conditions sHsps exists at relatively low levels in most cells and in non-phosphorylated forms (Figure 3). The 
activity of sHsps under these conditions is sufficient to maintain cellular proteostasis. Upon stress, the sHsps are 
rapidly phosphorylated, which modifies their oligomeric state and facilitates their translocation into the nucleus  
where they interact with and bind to destabilised proteins in danger of aggregating and precipitating. Prolonged 
or chronic cell stress (e.g. that which occurs during some diseases) leads to an increase in sHsp levels in the cell 
(due to their up-regulation as part of the heat-shock response pathway). This increase in expression facilitates the 
formation of a heterogeneous pool of sHsp oligomers (including phosphorylated and non-phosphorylated forms), 
which maximises the possible binding interactions of the sHsps with various intracellular target proteins. 
 
SECTION III:  sHsps and their roles in disease  
In extra-lenticular tissues, the roles played by sHsps may vary according to specific cell and tissue types. Further 
complicating the picture in vivo is that the entire range of interactions of sHsps with target proteins that may occur 
in the crowded environment of the cell are not easily replicated by in vitro experiments [6]. Just as the precise 
mechanism(s) of action of sHsps in protein stabilisation remain to be elucidated in vivo, the precise roles of sHsps 
in the cellular pathologies of many diseases also remain largely unclear.  As a result of their increased expression 
under a variety of cellular stresses, particularly those present in pathological states (i.e. heat /inflammation, 
oxidation, ischaemia), it is perhaps not surprising that sHsps and their (mal)function have been associated with a 
plethora of diseases including neurodegenerative diseases, multiple sclerosis and cancers [4-6,172-174].  
Elucidating the precise role(s) played by sHsps in the context of disease is complex as they may be present as a 
consequence or cause of the disease. Moreover, as a result of their ubiquitous role in interacting with and 
stabilising a wide range of partially unfolded proteins against aggregation, sHsps are involved in many processes 
central to disease development and manifestation. These include cellular growth and differentiation [90,175,176]; 
interaction with cytoskeletal components such as actin and intermediate filaments [6,177,178]; and apoptosis 
[179]. Several of the sHsp family members (Hsp27, Bc, Hsp20 and HSPB2) have been attributed a protective 
role in the development of neurodegenerative and neuromuscular diseases, roles thought to be related to their 
abilities to both stabilise target proteins and to interact with cytoskeletal elements as the key features of these 
diseases are protein aggregation and defective axonal transport [6].  
 
The role of sHsps in neurodegenerative disease 
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Bc is expressed at high levels in the neurons and glial cells of patients with neurodegenerative diseases such as 
Alzheimer’s (AD), Huntington’s, Alexander, Neuman-Pick, Creutzfeldt-Jakob (CJD) and amylotrophic lateral 
sclerosis (ALS) (summarised in [6]). Furthermore, Bc inhibits the in vitro aggregation of glial acidic fibrillary 
protein (GAFP) and -syn which are associated with Alexander and Parkinson’s disease (PD) pathologies, 
respectively [180,181]. Hsp20 and Hsp22 are also present at increased levels following neuronal stress associated 
with AD, PD, and ALS [4,182-185]. Hsp27 is also upregulated in AD and Neuman-Pick diseases [6]. Bc and/or 
Hsp27 have also been identified in the protein deposits characteristic of several neurodegenerative and 
neuromuscular diseases (see below), co-depositing with the protein or peptide identified as being responsible for 
the pathological features of the disease [84]. 
 
The Rosenthal fibres characteristic of Alexander disease constitute abnormal inclusions containing Bc (some of 
which is ubiquitinated) [186], Hsp27 and GAFP [187,188]. The involvement of Hsp27 and Bc in the formation 
of Rosenthal fibres within astrocytes is  believed to be a response to an as-yet unknown stress caused by the 
disease [83]. The close association of sHsps with intermediate filaments in these pathologies [187] indicates that 
sHsps may play a role in their structural rearrangement [189]. Rosenthal fibres accumulate as a result of 
insufficient protein degradation in the cell. Bc’s lysine residues, particularly the three in the solvent-exposed and 
highly flexible C-terminal extension (K166, K175 and K174) [16] serve as potential sites for the binding of 
ubiquitin in order to target the protein for degradation [190-192]. The presence of Bc-ubiquitin conjugates in 
such pathological inclusions implies a breakdown of the cell’s protein degradation system. 
The pathology of AD is characterised by extracellular accumulation of amyloid plaques and intracellular 
neurofibrillary tangles [193]. Amyloid plaques are composed primarily of A peptides which are derived from 
the abnormal processing of -amyloid precursor protein by -secretase. In patients with familial AD, 
overproduction of A leads to early onset AD [194-197]. The level of Bc expression in brains of patients 
suffering AD is markedly increased compared to that in the normal human brain [113,198] presumably due to the 
cellular stress caused by disease. We and others have shown that aggregation of A and its associated cellular 
toxicity is prevented by Bc [199] or its isolated ACD [26] and thus sHsp overexpression in the context of AD 
may be as a protective mechanism. Fändrich et al. have shown that there is an intracellular component to the 
aggregation and pathogenic nature of A which may explain the presence of Bc in the extracellular plaques of 
AD [200]. The intracellular neurofibrillary tangles characteristic of AD (and other ‘tauopathies’) contains 
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hyperphosphorylated tau protein [201]. Both Bc and Hsp27 are also found in these tangles, however, their 
contributions to the formation of these plaques and tangles, and hence the pathology of AD, remains unclear [202].   
 
The presence of Bc, Hsp27 and ubiquitin in CJD is thought to be related to the degenerative processes that 
neurons undergo as the disease manifests [191]. CJD is a transmissible spongiform encephalopathy resulting from 
the intracellular deposition of misfolded prion protein (PrPsc). The bovine precursor of this misfolded protein 
associates with Bc both in vitro and in vivo [203]. However, it remains unclear as to whether Bc acts to inhibit 
or enable the conversion of correctly folded prion to its toxic PrPsc form. Ubiquitinated Bc has also been 
identified by immunochemical analysis in cytoplasmic inclusions in brains of patients with multiple system 
atrophy [204]. More recently, it has been shown that the aggregation of SOD1, a major protein involved in the 
pathogenesis of ALS, is prevented by both Bc and Hsp27 [205,206] and that Hsp22, in concert with other 
chaperones, promotes autophagic removal of misfolded proteins in ALS [184]. 
 
PD is characterised by a gradual loss of dopaminergic neurons in the brain. The precise role of Bc (and other 
sHsps) in the development and progression of this disease is still unknown [207], despite the findings that the 
disease is characterised by ‘ballooned’ neurons [208] which express Bc [113]. Both PD and Huntington’s disease 
are intracellular protein aggregation diseases, like CJD. We have previously demonstrated that Bc prevents the 
aggregation of -syn, the principal protein in Lewy body deposits, and that Bc also binds to intact -syn fibrils 
to prevent their further growth [114,115,180]. Furthermore, several sHsps (Hsp20, Hsp22, HspB7 and HspB9) 
inhibit the aggregation of the polyQ huntingtin protein responsible for Huntington disease and also protect against 
cell death triggered by the deposition of the aberrant protein [4,209]. Our subsequent studies have shown, 
however, that polyQ aggregation occurs in stages, and while Bc potently inhibits the first stage of fibril formation 
by the polyQ protein, ataxin (responsible for spinocerebellar ataxia), through interaction with its Josephin 
(flanking) domain, the second stage of polyQ aggregation can still proceed [210]. The potency of sHsps in 
individual disease states therefore appears to be very much dependent on target protein aggregation models and 
specific sequences can modulate this effect. 
 
The role of sHsps in multiple sclerosis 
Multiple Sclerosis (MS) is a relatively common demyelinating neurodegenerative disease. The exact mechanism 
of demyelination is unknown but appears to be an autoimmune disorder, triggered by environmental factors (e.g. 
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viral infection). Patients with MS have numerous demyelinated plaques in the brain and spinal cord and these 
lesions have varying histopathological profiles depending on the stage of disease  (i.e. acute or chronic). 
Inflammation plays a central role in disease progression as macrophages initially phagocytose the degraded myelin 
to form an acute plaque (with other immune cells such as T-lymphocytes and plasma cells) before a reactive 
gliosis is established, leading to chronic inflammation and plaque formation. It has been shown that Bc is the 
most prominent protein present in plaques of MS patients [211] and the CRYAB gene is the most highly induced 
in plaque tissue compared to normal tissue [212]. The increased expression of Bc, along with other Hsps, is 
proposed to be part of the oligodendrocyte’s survival response [192]. Initial studies identifying Bc bound to 
antibodies in the sera of affected patients suggested Bc as an auto-antigen to human T-cells in MS [4,213,214]. 
Subsequent studies showed that most of the sHsps (HspB1-8) were capable of binding immunoglobulin molecules 
with varying affinities and through multiple binding sites [214]. The association of these proteins with antibodies 
in the context of MS therefore appears to be related to their intrinsic ability to bind immunoglobulins rather than 
any inherent immunogenic property of the sHsp itself.  As proposed by Clark and Muchowski [172], the up-
regulation of sHsps in diseases characterised by hyper- or autoimmune responses such as MS may lead to 
stabilisation of antigenic components by the chaperones which then act to exacerbate an immune response. 
 
 
The role of sHsps in cancer 
Several sHsps, particularly Hsp27 and Bc, have been identified as playing potential roles in the pathogenesis of 
cancer.  Both Ac and Bc have been found in a range of tumours  [84] and especially in high-grade tumours 
[215]. Hsp27 has been identified at high levels in metastatic tissues compared to non-metastatic tissues, indicating 
a role in the metastasis of cancer [216,217]. Indeed, the ability to regulate apoptosis and thus prolong cell life, 
which in some cases is tumorigenic, is a feature consistent with the finding that Hsp27 and Bc expression is 
associated with increased cellular resistance to cytostatic agents [218]. Interestingly, the metastatic properties of 
breast cancer cells can be inhibited by phosphorylation of Bc. Phosphorylation at S59 specifically reduces the 
anti-apoptotic action of the protein, by affecting oligomer formation [217,219].  
 
In terms of the mechanisms by which sHsps promote tumorigenesis, many pathways have been identified by 
which sHsps regulate both the intrinsic and extrinsic pathways of apoptosis. For example, Chen et al.  showed 
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that both Ac and Bc are able to bind to the pro-apoptotic Bcl-2 proteins Bax and Bcl-Xs, inhibiting their 
mitochondrial translocation and thereby switching off the intrinsic cell death pathway [215]. Specific naturally-
occurring mutations in the -crystallins (R116C Ac and R120G Bc) impair the ability of these sHsps to 
sequester Bax and Bcl-Xs  [220]. Previous work has also shown that Hsp27 interacts directly with Daxx to prevent 
Fas-mediated apoptosis [221], a cell death pathway that involves Hsp27 [222]. Future therapies may therefore 
include those which aim to suppress the action of sHsps in such situations [84]. For example, a recent clinical trial 
of an antisense oligonucleotide (ASO; OGX-427) designed to specifically inhibit the expression of Hsp27 for the 
treatment of prostate, bladder, breast and lung cancer has shown promising results [79]. 
 
The role of sHsps in cataract and myopathies 
Several naturally-occurring mutations in sHsps have been identified as being responsible for various forms of 
human cataract and myopathy. These will be discussed further in the following section describing the occurrence 
and phenotypic effects of specific mutations in sHsps. 
 
 
 
SECTION IV: Naturally-occurring mutations in sHsps – implications for altered function and disease 
Our understanding of the roles played by sHsps in disease aetiology has been increasingly enhanced by the 
identification of sHsp mutations directly associated with specific pathologies (Table 2). Typically, these mutations 
lead to altered chaperone function and therefore provide a clear link between molecular chaperone action and 
disease manifestation.  
 
Mutations in the -crystallin domain 
A naturally-occurring missense mutation (R120G) in the conserved ACD of Bc was first identified as being 
responsible for a form of desmin-related myopathy (DRM) [223]. R120G Bc is associated with aggregation of 
the intermediate filament protein, desmin, in the cytoplasm of myocytes [224]. Desmin is essential for tensile 
strength in myofibrils of striated muscle and as a result DRM manifests with progressive muscle weakness. 
Moreover, gene mutations producing DRM are clinically heterogeneous with affected individuals often also 
exhibiting cardiomyopathy and cataract [223,225]. The formation of desmin aggregates was initially attributed to 
loss of chaperone function in Bc as a result of the R120G mutation, a hypothesis supported by the finding that 
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formation of desmin aggregates could be delayed or prevented in vivo by the addition of wild-type Bc or other 
molecular chaperones [226]. Subsequent studies by our group and others have shown that the R120G mutation 
causes significant structural changes in Bc compared to the wild-type protein, leading to a loss of chaperone 
activity in vitro [227] and an inherent instability in the mutated protein [228]. Similarly, D140N Bc, a mutant 
identified in relation to congenital lamellar cataract, exhibits abnormal oligomerisation and impaired chaperone 
activity [229,230]. Recent biophysical studies by Hilton et al. [12] support the rationale that mutations in the ACD 
of Bc interfere with important transient interactions between subunits and therefore impact on the association 
and dissociation properties of the oligomeric form. The locations of naturally-occurring, disease-associated 
mutations in a model of the Bc monomer are shown in Fig. 4. 
 
Mutation in Ac at the equivalent residue to R120G in Bc (i.e. R116C) results in hereditary cataract [231] and 
similar mutations in the gene coding for Ac have profound effects on lens opacity [232]. Mutation of R116 in 
the ACD of Ac causes a decrease in chaperone activity and subsequent aggregation of the natural target proteins 
of Ac in the lens (the - and -crystallins) [172]. Altered chaperone activity in R116C Ac (as with R120G Bc) 
results from secondary and tertiary structural changes and increased oligomeric size as a result of the mutation 
[233-235]. The substitution of an arginine for a cysteine at this position exposes a previously buried residue which 
most likely disrupts salt bridges and potentially leads to the formation of non-native, inter-subunit disulphide 
bonds [236]. It is highly likely therefore that perturbation at this site is the reason for the abnormal oligomeric 
assembly of R116C Ac. This same residue is affected in the R116H mutant of Ac which also causes cataract 
[237]. As discussed in Section I, the interaction between A- and Bc is crucial to the maintenance of lens 
transparency. The R116C mutation in Ac also leads to a reduction in its protective ability against epithelial cell 
apoptosis in the lens [238]. A number of other site-specific mutations involving residues within the ACD have 
been found to be responsible for the development of either whole (lenticular) or nuclear cataract in humans (R49C 
and G98R Ac) [239], or in mice (R54C/Y118D Ac) [240]. 
 
Six naturally-occurring mutations in Hsp27 have been identified that are associated with Charcot-Marie-Tooth 
(CMT) disease, an inherited motor and sensory neuropathy, and distal hereditary motor neuropathy (HMN). Three 
of these mutations, R127W, S135F (one causing CMT and the other HMN) and R136W, are located in the ACD 
[241]. Neuronal cells transfected with the mutant Hsp27s are less viable than those expressing wild-type Hsp27 
22 
 
and mutation also leads to altered neurofilament assembly within cells [241]. Similar mutations in the ACD of 
Hsp22, (i.e. K141E [242], K141T [243] and K141N [242,244,245]), also give rise to CMT disease, indicating a 
critical role for sHsps in both motor and sensory neurons. R140G [246] and K141Q [247] mutations in Hsp27 
cause distal HMN. 
 
Mutations in the C-terminal region 
Outside of the ACD, naturally-occurring mutations in the C-terminal regions of both Ac and Bc are associated 
with disease. Mutation of conserved residues in Bc, R157H and G154S, lead to dilated cardiomyopathies but 
not cataract [248,249]. As discussed above, another form of DRM arises from a deletion mutation (Q151X) in 
Bc [250]. Similarly, several other naturally-occurring mutations in the C-terminal region of Hsp27, T151I [241], 
T180I [251], P182L [241] and P182S [252] cause HMN. Other rarer forms of fibrillar neuropathy have been 
identified, with deletions in the gene encoding Bc (CRYAB) resulting in the absence of the protein from affected 
muscle fibres [253]. A naturally-occurring deletion of a single nucleotide base in the CRYAB gene has been 
described and leads to a frameshift mutation in the C-terminal region of the resulting Bc protein [229]. 
Replacement of the wild-type sequence after residue 149 with 35 novel residues (450delA) results in posterior 
polar cataract [229]. Similarly, deletion of two bases in CRYAB leads to truncation at position 464 (del464CT), 
giving a myofibrillar myopathy phenotype [250]. These provide further evidence for the importance of the C-
terminal region in the function of sHsps. The complex phenotypical profiles associated with naturally-occurring 
mutations of Bc and Hsp27 are a consequence of their widespread tissue distributions (which largely overlap) 
and their wide array of cellular functions.  
 
Mutations in the N-terminal region 
In the N-terminal region, there are small regions of high (≥ 85%) sequence identity between members of the sHsp 
family. Thus, residues 48-55 in Bc encompass the RLFDQxFG motif, which is also present in Hsp27 and Hsp20 
[254]. Several naturally-occurring mutations in the N-terminal region of Hsp27 have been shown to exist in 
individuals affected by distal HMN (Table 2; [246]). 
 
The P20S mutant of Bc is the only cataract-causing mutation to be identified outside the ACD, but it affects a 
highly conserved N-terminal residue that also impairs the chaperone activity of Ac [255]. The naturally-
occurring mutation W9X in Ac has also been identified in individuals with cataract [256,257], as have mutations 
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involving R21 (Table 1; [258-260]). Similarly, R49C [256] and R54H Ac [240] cause cataract, with R49C Ac 
exhibiting impaired chaperone function in vivo, resulting in greater perturbation of oligomer distribution and 
higher levels of cell death than even R116C Ac [256]. Furthermore, the same mutation induces apoptosis in 
human lens epithelial cells, an effect thought to be related to aberrant phosphorylation at S19, S45 and S59 of 
Bc, leading to its nuclear import and accumulation which results in subsequent cell death [255].  
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Future perspectives 
From the above, it is apparent that there is still a great deal to learn about sHsps – they are an enigmatic class of 
molecular chaperone proteins. They appear to have many roles in cells, all of which are based around their ability 
to stabilise other proteins, thereby preventing their misfolding and potential aggregation under both normal 
(constitutive) and abnormal (stress) conditions in the cell. Their ability to interact with amyloid fibril -forming 
proteins at the various stages of their aggregation pathway also imparts a multi-functional dimension to sHsp 
chaperone activity. 
 
To rationalise sHsp functions will require a continued concerted effort on various fronts to:  
1. Understand fully the mechanism and role of sHsp subunit exchange (if any) in chaperone action. 
2. Understand the functional role of each of the three sHsp structural regions. 
3. Determine an accurate quaternary structure for B-crystallin and other sHsps (which, most likely, will 
provide major insight into points 1 and 2).  
4. Understand, and explain, the role of post-translational modification, particularly phosphorylation, in 
sHsp chaperone action. 
5. Understand why nature provided so many distinct sHsps – a feature indicating a need for diversity and/or 
compartmentalisation of sHsp functionalities. 
With the rapid advances in the last five years of biophysical and spectroscopic techniques that can be used to study 
large and dynamic protein complexes (e.g. mass spectrometry, X-ray crystallography, solution and solid state 
NMR, electron microscopy, SAXS and SANS), there is vastly increased scope for examining the structure and 
mode of action of the previously elusive dynamic and polydisperse mammalian sHsps. As a result, many of these 
powerful techniques, previously applied in isolation, are being used in combination with significant success to 
build up a more complete picture of sHsp structure, dynamics and mechanism of chaperone action [27-29]. 
Furthermore, with the advent of single-molecule fluorescence techniques, whereby individual protein molecules 
can be studied in isolation, avoiding the bulk averaging that can mask rare or short-lived species, the next decade 
holds much promise with regards to unravelling the precise structure-function relationship of sHsps. The 
culmination of this work will be the development of molecules that can regulate the activity of sHsps in the context 
of providing therapies for treatment of the wide range of diseases associated with protein misfolding and 
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aggregation, many of which (e.g. AD, PD and cataract) are becoming increasingly prevalent amongst our ageing 
population.  
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Tables 
Table 1 Tissue distribution of the major sHsps 
sHsp Alternative name Tissue distribution 
Ac HSPB4 Eye lens, spleen, thymus [261] 
Bc HSPB5 Eye lens, retina, heart, skeletal muscle, skin, brain, spinal cord, kidneys, lungs 
[44,64,65], cochlea [66], lacrimal gland duct & tears [68], sciatic nerve [6] 
Hsp27 HSPB1 Skeletal, cardiac and smooth muscle, brain and spinal cord (summarised in 
[6]) 
Hsp22 HSPB8 Muscle, brain, spinal cord (summarised in [6]) 
Hsp20 HSPB6 Skeletal, cardiac and smooth muscle , brain, spinal cord, sciatic nerve 
(summarised in [6]) 
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Table 2 Disease-causing sHsp mutations in humans 
sHsp Mutant Disease 
Ac W9X, R12C, R12W, R21L, R49C, 
R54H, G98R, R116C*, R116H* 
Cataract [231,237,239,240,256,258-260,262] 
Bc R120G* Desmin-related myopathy, cataract [223] 
Bc P20S, R56W, D140N, 450delA Cataract [229,230,255,263] 
Bc R157H, G154S Dilated cardiomyopathy [248,249] 
Bc Q151X (STOP) Desmin-related myopathy [127,250] 
Bc 454delCT CRYAB gene Desmin-related myopathy [250] 
Bc 450delA CRYAB gene Cataract [229] 
Hsp27 R127W, S135F, R136W, T151I, 
P182L  
Distal hereditary motor neuropathy, motor and sensory 
neuropathy, Charcot-Marie-Tooth disease [241] 
Hsp27 P182S Distal hereditary motor neuropathy [252] 
Hsp22 K141N*, K141E*, K141Q Distal hereditary motor neuropathy [242,244] 
Hsp27 T180I Distal hereditary motor neuropathy [251] 
Hsp22 K141N* Charcot-Marie-Tooth disease [245] 
Hsp22 K141T* Charcot-Marie-Tooth disease [243] 
*Residue 116, 120 and 141 in A-, Bc and Hsp22, respectively, are equivalent. 
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Figure Legends 
Fig. 1A Schematic arrangement of the various structural regions in human Bc. The -sheet-rich ACD is flanked by the 
relatively unstructured N- and C-terminal regions. The latter contains the highly conserved ‘IXI’ sequence and the unstructured 
and flexible C-terminal extension encompassing the last 12 amino acids. 
 
Fig. 1B Crystal structure of the Methanococcus jannaschii Hsp16.5 24-mer oligomer showing its large central cavity [20]. 
Each colour represents an individual subunit within the oligomer.  Reprinted with permission from [20]. 
 
Fig. 1C X-ray crystal structure of the ACD and C-terminal region of Bc without its flexible C-terminal extension [12]. The 
Bc dimer is shown in which the six -strands of each ACD are arranged in an immunoglobulin-like fold. The intra-dimer 
contacts arise between -strands 6 and 7 of each subunit, arranged in an antiparallel (AP) manner. The inter-dimer interaction 
is also shown in which an Bc peptide from the C-terminal region of one subunit encompassing a palindromic nine amino 
acid sequence (residues 156 to 164), including the ‘IXI’ sequence (IPI; residues 159 to 161), interacts with the fourth and 
eighth -strands of the adjacent Bc subunit. Adapted and used with permission from [12]. 
 
 
Fig. 2 The chaperone mechanism of sHsps  
Multiple partially-folded protein intermediate states populate the folding/unfolding pathway of a protein. The mechanism by 
which sHsps, such as αB-c, prevent target protein aggregation (either amorphous or fibrillar) is dictated by the conformational 
stability and exposed hydrophobicity of the precursor protein intermediates. High affinity interactions occur with highly 
destabilised intermediates (which exceed the threshold of binding) and these are sequestered into stable high molecular mass 
complexes. Target proteins in these complexes can be re-folded through the action of other ATP-dependent chaperones or 
shuttled for degradation or via chaperone-mediated autophagy. Alternatively, weak, transient interactions occur with more 
stable protein intermediates, which re-direct them back to the folding pathway so as to facilitate their re-folding. sHsps can 
also interact with pre-fibrillar and fibrillar aggregates formed by target proteins. By binding to these species sHsps stabilise 
them preventing their further elongation and fibril fragmentation and secondary nucleation events, which can be the main 
source of toxic oligomeric species formed during amyloid fibrillar aggregation. (Adapted from [95]). 
 
Fig 3. The effect of phosphorylation on sHsps in cells  
Under basal conditions in the cell sHsps act to maintain proteostasis by buffering against protein aggregation of target proteins. 
Conditions of cellular stress (e.g. a change in pH, oxidative stress or increase in temperature) are sensed by the cell, triggering 
a signalling pathway that results in the activation of protein kinases, including mitogen activated protein (MAP) kinases which 
can phosphorylate sHsps, such as B-c and Hsp27. Phosphorylation of sHsps decreases their oligomeric size and causes some 
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phosphorylated sHsps to be translocated to the nucleus. In doing so, phosphorylation boosts the chaperone activity of sHsps 
against target proteins in danger of aggregating and precipitating as a result of the cellular stress. Prolonged exposure to stress 
leads to the activation of the transcription factor heat-shock factor 1 (HSF1), which self- associates into trimers and then 
relocates to the nucleus, stimulating transcription of heat-shock response genes including the sHsps Hsp27, Bc and Hsp22. 
Newly translated sHsps oligomerise with existing sHsps leading to the formation of a heterogeneous pool of sHsp oligomers 
(including phosphorylated and non-phosphorylated forms), which maximises their possible binding interactions with 
intracellular target proteins to prevent their aggregation. The Venn diagram in the centre represents the group of aggregation-
prone target proteins with which the non-phosphorylated (blue), phosphorylated (red) or heterogeneous (purple) sHsp 
oligomers interact. 
 
Fig. 4. Homology model of the human Bc monomer showing approximate locations of naturally-occurring, disease-causing 
mutations. Adapted and reused with permission from  [264]. Copyright (2014) American Chemical Society.  
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